INTERNET1.gif
  Home     Media Contacts     Links     Sitemap     MRMC globe4.gif     MEDCOM globe4.gif     Army globe4.gif     AKO globe4.gif     CTC globe4.gif     FAQ          
                                                                                                                                                               


New Advances for a Malaria Vaccine

It takes the right mix of proteins

DuttaBest.jpg

December 26, 2013 (Silver Spring, Md.) – A vaccine containing recombinant Apical Membrane Antigen-1 (AMA1) proteins derived from four laboratory strains of the malaria parasite Plasmodium falciparum could inhibit the invasion of many diverse parasites collected from Africa and Asia. The results were published in the online journal PLOS Pathogens.

“A first generation monovalent AMA1 vaccine, tested in Malian children, had earlier failed to protect broadly against malaria. Faced with an extremely diverse parasite population, we set out to find ways to make the vaccine based on the AMA1 protein effective against multiple parasite strains,” said, Dr. Sheetij Dutta, Ph.D., Chief of the Structural Vaccinology Laboratory at the Malaria Vaccine Branch at the Walter Reed Army Institute of Research (WRAIR). “Antibodies against a quadrivalent AMA1 vaccine (Quadvax), surprisingly inhibited the invasion of 22 non-vaccine strains and the conserved epitopes targeted by anti-Quadvax were mapped to two functional regions of the AMA1 molecule. These novel broadly inhibitory epitopes could now be targeted to improve AMA1-based malaria vaccines.” said Dutta.

“Our data has wide implications for vaccine development against other diverse pathogens, such as HIV and influenza, because polyvalent vaccines, those containing a mix of immune-system stimulating proteins from multiple strains, are generally believed to protect by inducing a multitude of type-specific inhibitory antibodies. However, our data showed that a vaccine containing only a small subset of carefully selected diverse allelic proteins could redirect antibodies towards broadly inhibitory conserved epitopes.” said Dutta.

Scientists at the National Institutes of Health, The Burnet Institute and the La Trobe University (Australia) collaborated in this joint effort and the project was supported by grants from the USAID Malaria Vaccine Development Program, Malaria Vaccine Initiative and the U.S. Department of Defense (DoD).




Last Modified Date: 09-September-2016



This Web site provides an introduction to the U.S. Army Medical Research and Materiel Command (USAMRMC) and contains official Government information. Its use is intended for members of the general public, news media and Army Medical Department beneficiaries.
Please address questions or concerns about this website to the Public Affairs Office via e-mail or by telephone at 301-319-9471.